Calcium-channel blockade and incidence of cancer in aged populations

Marco Pahor, Jack M. Guralnik, Luigi Ferrucci, Maria Chiara Corti, Marcel E. Salive, James R. Cerhan, Robert B. Wallace, Richard J. Havlik

Research output: Contribution to journalArticle

Abstract

Background: Calcium-channel blockers can alter apoptosis, a mechanism for destruction of cancer cells. We examined whether the long-term use of calcium-channel blockers is associated with an increased risk of cancer. Methods: Between 1988 and 1992 we carried out a prospective cohort study of 5052 people aged 71 years or more and who lived in three regions of Massachusetts, Iowa, and Connecticut USA. Those taking calcium-channel blockers (n = 451) were compared with all other participants (n = 4601). The incidence of cancer was assessed by survey of hospital discharge diagnoses and causes of death. These outcomes were validated by the cancer registry in the one region where it was available. Demographic variables, disability, cigarette smoking, alcohol consumption, blood pressure, body-mass index, use of other drugs, hospital admissions for other causes, and comorbidity were all assessed as possible confounding factors. Findings: The hazard ratio for cancer associated with calcium channel blockers (1549 person-years, 47 events) compared with those not taking calcium-channel blockers (17225 person-years, 373 events) was 1.72 (95% CI 1.27-2.34, p = 0.0005), after adjustment for confounding factors. A significant dose-response gradient was found. Hazard ratios associated with verapamil, diltiazem, and nifedipine did not differ significantly from each other. The results remained unchanged in community-specific analyses. The association between calcium-channel blockers and cancer was found with most of the common cancers. Interpretation: Calcium-channel blockers were associated with a general increased risk of cancer in the study populations, which suggested a common mechanism. These observational findings should be confirmed by other studies.

Original languageEnglish (US)
Pages (from-to)493-497
Number of pages5
JournalThe Lancet
Volume348
Issue number9026
DOIs
StatePublished - Aug 24 1996
Externally publishedYes

Fingerprint

Calcium Channels
Calcium Channel Blockers
Incidence
Population
Neoplasms
Diltiazem
Nifedipine
Verapamil
Alcohol Drinking
Registries
Comorbidity
Cause of Death
Body Mass Index
Cohort Studies
Smoking
Demography
Prospective Studies
Apoptosis
Blood Pressure
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pahor, M., Guralnik, J. M., Ferrucci, L., Corti, M. C., Salive, M. E., Cerhan, J. R., ... Havlik, R. J. (1996). Calcium-channel blockade and incidence of cancer in aged populations. The Lancet, 348(9026), 493-497. https://doi.org/10.1016/S0140-6736(96)04277-8

Calcium-channel blockade and incidence of cancer in aged populations. / Pahor, Marco; Guralnik, Jack M.; Ferrucci, Luigi; Corti, Maria Chiara; Salive, Marcel E.; Cerhan, James R.; Wallace, Robert B.; Havlik, Richard J.

In: The Lancet, Vol. 348, No. 9026, 24.08.1996, p. 493-497.

Research output: Contribution to journalArticle

Pahor, M, Guralnik, JM, Ferrucci, L, Corti, MC, Salive, ME, Cerhan, JR, Wallace, RB & Havlik, RJ 1996, 'Calcium-channel blockade and incidence of cancer in aged populations', The Lancet, vol. 348, no. 9026, pp. 493-497. https://doi.org/10.1016/S0140-6736(96)04277-8
Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR et al. Calcium-channel blockade and incidence of cancer in aged populations. The Lancet. 1996 Aug 24;348(9026):493-497. https://doi.org/10.1016/S0140-6736(96)04277-8
Pahor, Marco ; Guralnik, Jack M. ; Ferrucci, Luigi ; Corti, Maria Chiara ; Salive, Marcel E. ; Cerhan, James R. ; Wallace, Robert B. ; Havlik, Richard J. / Calcium-channel blockade and incidence of cancer in aged populations. In: The Lancet. 1996 ; Vol. 348, No. 9026. pp. 493-497.
@article{5cb55d7ef70e450c8869ca9d0f98a8f9,
title = "Calcium-channel blockade and incidence of cancer in aged populations",
abstract = "Background: Calcium-channel blockers can alter apoptosis, a mechanism for destruction of cancer cells. We examined whether the long-term use of calcium-channel blockers is associated with an increased risk of cancer. Methods: Between 1988 and 1992 we carried out a prospective cohort study of 5052 people aged 71 years or more and who lived in three regions of Massachusetts, Iowa, and Connecticut USA. Those taking calcium-channel blockers (n = 451) were compared with all other participants (n = 4601). The incidence of cancer was assessed by survey of hospital discharge diagnoses and causes of death. These outcomes were validated by the cancer registry in the one region where it was available. Demographic variables, disability, cigarette smoking, alcohol consumption, blood pressure, body-mass index, use of other drugs, hospital admissions for other causes, and comorbidity were all assessed as possible confounding factors. Findings: The hazard ratio for cancer associated with calcium channel blockers (1549 person-years, 47 events) compared with those not taking calcium-channel blockers (17225 person-years, 373 events) was 1.72 (95{\%} CI 1.27-2.34, p = 0.0005), after adjustment for confounding factors. A significant dose-response gradient was found. Hazard ratios associated with verapamil, diltiazem, and nifedipine did not differ significantly from each other. The results remained unchanged in community-specific analyses. The association between calcium-channel blockers and cancer was found with most of the common cancers. Interpretation: Calcium-channel blockers were associated with a general increased risk of cancer in the study populations, which suggested a common mechanism. These observational findings should be confirmed by other studies.",
author = "Marco Pahor and Guralnik, {Jack M.} and Luigi Ferrucci and Corti, {Maria Chiara} and Salive, {Marcel E.} and Cerhan, {James R.} and Wallace, {Robert B.} and Havlik, {Richard J.}",
year = "1996",
month = "8",
day = "24",
doi = "10.1016/S0140-6736(96)04277-8",
language = "English (US)",
volume = "348",
pages = "493--497",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9026",

}

TY - JOUR

T1 - Calcium-channel blockade and incidence of cancer in aged populations

AU - Pahor, Marco

AU - Guralnik, Jack M.

AU - Ferrucci, Luigi

AU - Corti, Maria Chiara

AU - Salive, Marcel E.

AU - Cerhan, James R.

AU - Wallace, Robert B.

AU - Havlik, Richard J.

PY - 1996/8/24

Y1 - 1996/8/24

N2 - Background: Calcium-channel blockers can alter apoptosis, a mechanism for destruction of cancer cells. We examined whether the long-term use of calcium-channel blockers is associated with an increased risk of cancer. Methods: Between 1988 and 1992 we carried out a prospective cohort study of 5052 people aged 71 years or more and who lived in three regions of Massachusetts, Iowa, and Connecticut USA. Those taking calcium-channel blockers (n = 451) were compared with all other participants (n = 4601). The incidence of cancer was assessed by survey of hospital discharge diagnoses and causes of death. These outcomes were validated by the cancer registry in the one region where it was available. Demographic variables, disability, cigarette smoking, alcohol consumption, blood pressure, body-mass index, use of other drugs, hospital admissions for other causes, and comorbidity were all assessed as possible confounding factors. Findings: The hazard ratio for cancer associated with calcium channel blockers (1549 person-years, 47 events) compared with those not taking calcium-channel blockers (17225 person-years, 373 events) was 1.72 (95% CI 1.27-2.34, p = 0.0005), after adjustment for confounding factors. A significant dose-response gradient was found. Hazard ratios associated with verapamil, diltiazem, and nifedipine did not differ significantly from each other. The results remained unchanged in community-specific analyses. The association between calcium-channel blockers and cancer was found with most of the common cancers. Interpretation: Calcium-channel blockers were associated with a general increased risk of cancer in the study populations, which suggested a common mechanism. These observational findings should be confirmed by other studies.

AB - Background: Calcium-channel blockers can alter apoptosis, a mechanism for destruction of cancer cells. We examined whether the long-term use of calcium-channel blockers is associated with an increased risk of cancer. Methods: Between 1988 and 1992 we carried out a prospective cohort study of 5052 people aged 71 years or more and who lived in three regions of Massachusetts, Iowa, and Connecticut USA. Those taking calcium-channel blockers (n = 451) were compared with all other participants (n = 4601). The incidence of cancer was assessed by survey of hospital discharge diagnoses and causes of death. These outcomes were validated by the cancer registry in the one region where it was available. Demographic variables, disability, cigarette smoking, alcohol consumption, blood pressure, body-mass index, use of other drugs, hospital admissions for other causes, and comorbidity were all assessed as possible confounding factors. Findings: The hazard ratio for cancer associated with calcium channel blockers (1549 person-years, 47 events) compared with those not taking calcium-channel blockers (17225 person-years, 373 events) was 1.72 (95% CI 1.27-2.34, p = 0.0005), after adjustment for confounding factors. A significant dose-response gradient was found. Hazard ratios associated with verapamil, diltiazem, and nifedipine did not differ significantly from each other. The results remained unchanged in community-specific analyses. The association between calcium-channel blockers and cancer was found with most of the common cancers. Interpretation: Calcium-channel blockers were associated with a general increased risk of cancer in the study populations, which suggested a common mechanism. These observational findings should be confirmed by other studies.

UR - http://www.scopus.com/inward/record.url?scp=0030600342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030600342&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(96)04277-8

DO - 10.1016/S0140-6736(96)04277-8

M3 - Article

C2 - 8757150

AN - SCOPUS:0030600342

VL - 348

SP - 493

EP - 497

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9026

ER -